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Background
In August 2004, Schwarz Pharma received the
FDA’s approval of Parcopa (carbidopa-levodopa
orally disintegrating tablets) for treating
Parkinson’s disease. It is similar to immediate
release Sinemet and the generic equivalents but
differs in its unique dissolving formulation. The
new RapiTab dosage form dissolves rapidly on
the tongue without the need for water. This is
especially useful for Parkinson’s patients who
often have difficulty swallowing.
In a 2003 national survey, it was found that
40% of adults experienced difficulty in
swallowing pills. Of these adults, 26% reported
some form of swallowing-related medication noncompliance.1

Manufacturer
Schwarz Pharma
Milwaukee, WI 53201
www.schwarzusa.com
800-558-5114

Patient Instructions
Phenylketonuric patients should be informed
that Parcopa contains phenylalanine. The orallydisintegrating 10-100 mg and the 25-100 mg
tablets contain 3.4 mg per tablet. The 25-250 mg
tablets contain 8.4 mg of phenylalanine per tablet.
Patients should be advised to remove tablets
from the bottle just prior to use. They should
have dry hands and immediately place the tablet
on their tongue.

Product

Commentary

Parcopa is available in three strengths of the
carbidopa-levodopa combination: 10 mg-100 mg,
25 mg-100 mg, and 25 mg-250 mg. It is not rated
as a therapeutic equivalent to immediate-release
Sinemet or Sinemet generic equivalents.2 It is a
therapeutic alternative for patients with
swallowing difficulties.
The Parcopa is mint-flavored and dissolves
rapidly on the tongue. It can be swallowed with
or without water.
Parcopa carries the same indications,
contraindications, warnings, precautions, adverse
reactions, drug interactions, and dosage
recommendations as with Sinemet. Like Sinemet,
it is an immediate-release formulation designed to
begin release of ingredients within 30 minutes.3,4
Parcopa can be packaged in conventional
prescription bottles or in blister packs without
concern for durability as is the case with some
rapidly dissolving tablets.

The average wholesale cost for Parcopa is
approximately 40% more than for brand name
Sinemet.5 This difference in cost may be offset by
improved patient compliance and quality of life in
Parkinson’s patients who have difficulty
swallowing.
Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.
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